New Study Shows Verzenio Extends Life for Early Breast Cancer Patients
A major study by Eli Lilly has found that patients with early-stage breast cancer who took Verzenio along with standard […]
Novo Nordisk Partners with Replicate Bioscience to Develop New Obesity and Diabetes Treatments
Novo Nordisk, the company behind popular weight loss and diabetes drugs Ozempic and Wegovy, is teaming up with Replicate Bioscience
Pharmaceutical Mergers and Acquisitions: What You Need to Know
Stay informed about the latest in drug development with BioPharma Dive’s free newsletter, delivered straight to your inbox. In the
Eli Lilly and Novo Nordisk Compete in the Growing Obesity Drug Market
The obesity drug market is currently dominated by two major players: Eli Lilly and Novo Nordisk. Both companies are working
Health Leaders Consider Tighter Rules on Drug Ads Aimed at Consumers
A report from the Make America Healthy Again (MAHA) Commission was delayed earlier this month, but leaked documents reveal plans
FDA Gives Fast-Track Status to New Lung Cancer Treatment
The US Food and Drug Administration (FDA) has given special recognition to a new experimental drug called izalontamab brengitecan (iza-bren).
Pharmaceutical News
Eli Lilly’s Neuroscience Leader Anne White to Retire After 30 Years
Anne White, the Executive Vice President and President of Lilly Neuroscience at Eli Lilly and Company, will retire at the
New Blood Test Could Replace Tissue Biopsies for Cancer Patients
In this project, ANGLE’s research team will use the Parsortix system to collect cancer cells from the blood of cancer
Study Shows How Better Screening Helps People with Substance Use Disorder Fight Infections
The US Centers for Disease Control and Prevention (CDC) reports that about one in six Americans struggles with substance use
AstraZeneca’s Breakthrough in Lung Cancer Treatment: Targeting the EGFR Mutation
AstraZeneca’s journey in lung cancer treatment began in 2003 with a drug called Iressa, which targeted a specific gene mutation